| Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects |
Evaluate Jazz's (JAZZ) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance. |
zacks.com |
2025-05-13 14:22:16 |
Czytaj oryginał (ang.) |
| JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook |
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition. |
zacks.com |
2025-05-07 16:55:34 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript |
Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Jeff Macdonald - Executive Director, Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Renee Gala - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D and Chief Medical Officer Phil Johnson - Chief Financial Officer Conference Call Participants Jason Gerberry - Bank of America Jessica Fye - JP Morgan David Amsellem - Piper Sandler Marc Goodman - Leerink Partners. Annabel Samimy - Stifle Joseph Thome - TD Cowen Gregory Renza - RBC Capital Markets Joel Beatty - Baird Ami Fadia - Needham Ashwani Verma - UBS Mohit Bansal - Wells Fargo Gary Nachman - Raymond James Joon Lee - Truist Securities Operator Hello and thank you for standing by. |
seekingalpha.com |
2025-05-07 03:06:19 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings |
Although the revenue and EPS for Jazz (JAZZ) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-06 23:30:31 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates |
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $1.68 per share, missing the Zacks Consensus Estimate of $4.51 per share. This compares to earnings of $2.68 per share a year ago. |
zacks.com |
2025-05-06 22:20:40 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance |
– Total revenues of $898 million in 1Q25 –– Xywav ® and Epidiolex ® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 –– Completed submission of sNDA for Zepzelca ® in 1L ES-SCLC –– Affirming 2025 revenue guidance; updating financial guidance to reflect Chimerix acquisition and impact of certain Xyrem® antitrust litigation settlements – DUBLIN , May 6, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2025 and updated financial guidance for 2025. "In the first quarter of 2025, our focus on commercial execution resulted in total revenues of $898 million, led by the strong performance of Xywav and Epidiolex. |
prnewswire.com |
2025-05-06 20:05:00 |
Czytaj oryginał (ang.) |
| Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-05-05 14:46:25 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference |
DUBLIN , April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. |
prnewswire.com |
2025-04-30 20:15:00 |
Czytaj oryginał (ang.) |
| Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings |
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week. |
zacks.com |
2025-04-30 12:20:39 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? |
Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-29 15:06:12 |
Czytaj oryginał (ang.) |
| 3 Unconventional Cannabis Stocks to Watch in 2025 |
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025. |
zacks.com |
2025-04-29 13:15:40 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer |
DUBLIN , April 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.1 "This positive CHMP opinion is a welcome step for physicians and patients in Europe who face a critical unmet need in HER2-positive biliary tract cancers, a rare and aggressive group of cancers with poor prognosis and limited treatment options," said Robert Iannone, MD., M.S.C.E., executive vice president, global head of research and development, and chief medical officer of Jazz Pharmaceuticals. |
prnewswire.com |
2025-04-25 15:27:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma |
Statistically significant and clinically meaningful progression-free survival (PFS) and overall survival (OS) data for Zepzelca® (lurbinectedin) and atezolizumab (Tecentriq®) combination underscore potential of first-line maintenance therapy for extensive-stage small cell lung cancer, a much-needed advancement for patients Long-term outcomes and survival data for Ziihera ® (zanidatamab-hrii) highlight its potential to reshape the treatment paradigm for newly diagnosed HER2+ gastroesophageal cancer patients Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data For U.S. media and investors only DUBLIN , April 23, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present seven abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 30-June 3, 2025, in Chicago and online. The presentations will feature data from clinical trials evaluating Zepzelca® (lurbinectedin), Ziihera® (zanidatamab-hrii), Vyxeos® (daunorubicin and cytarabine) and investigational dordaviprone (ONC201). |
prnewswire.com |
2025-04-23 20:15:00 |
Czytaj oryginał (ang.) |
| Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak |
CBOE, AGNC, JAZZ, AES and CNSWF are some of the stocks with high ROE to profit from as markets expect the tariff war to end soon. |
zacks.com |
2025-04-23 16:20:38 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 |
DUBLIN , April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. |
prnewswire.com |
2025-04-22 20:15:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Completes Acquisition of Chimerix |
- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need - DUBLIN , April 21, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz. |
prnewswire.com |
2025-04-21 20:05:00 |
Czytaj oryginał (ang.) |
| JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? |
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025. |
zacks.com |
2025-04-21 12:40:38 |
Czytaj oryginał (ang.) |
| JAZZ vs. ARGX: Which Stock Is the Better Value Option? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now? |
zacks.com |
2025-04-17 16:40:36 |
Czytaj oryginał (ang.) |
| Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2025-04-17 14:45:53 |
Czytaj oryginał (ang.) |
| Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? |
Not your typical cannabis play. Discover why Jazz Pharma's FDA-approved CBD drug could make it a top cannabis stock to watch in 2025. |
zacks.com |
2025-04-17 12:50:56 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals: Decent 2025 Outlook, Extended Timeline For Zanidatamab |
Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates, and the 2025 revenue outlook is slightly below consensus. The delay in zanidatamab's phase 3 trial results is slightly disappointing but could indicate a better-than-expected treatment effect. I continue to see Jazz as a valuation re-rating candidate, driven by zanidatamab and Zepzelca, return to growth and reduced perceptions of the risks for the oxybate franchise. |
seekingalpha.com |
2025-02-26 17:15:33 |
Czytaj oryginał (ang.) |
| Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-02-26 12:45:52 |
Czytaj oryginał (ang.) |
| Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations |
Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations. |
zacks.com |
2025-02-26 10:51:11 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Jazz (JAZZ) Q4 Earnings: A Look at Key Metrics |
While the top- and bottom-line numbers for Jazz (JAZZ) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. |
zacks.com |
2025-02-25 21:35:29 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals (JAZZ) Tops Q4 Earnings and Revenue Estimates |
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $6.60 per share, beating the Zacks Consensus Estimate of $5.79 per share. This compares to earnings of $5.02 per share a year ago. |
zacks.com |
2025-02-25 20:50:47 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance |
– Record total revenues of $4.1 billion in 2024 and $1.1 billion in 4Q24 –– Xywav ® and Epidiolex ® revenues grew 16% and 15% year-over-year, respectively, in 2024 –– Oncology revenues grew 9% year-over-year in 2024, surpassed $1.1 billion –– Ziihera ® approved in 2L HER2+ (IHC3+) BTC; first sales achieved in December 2024 –– 2025 guidance reflects continued top- and bottom-line growth – DUBLIN , Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025. "2024 was another strong year as our proven team delivered significant top- and bottom-line growth along with record total revenues of over $4 billion. |
prnewswire.com |
2025-02-25 18:05:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference |
DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. |
prnewswire.com |
2025-02-20 18:15:00 |
Czytaj oryginał (ang.) |
| Jazz (JAZZ) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures |
Get a deeper insight into the potential performance of Jazz (JAZZ) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-02-20 12:20:53 |
Czytaj oryginał (ang.) |
| Jazz (JAZZ) Surges 5.2%: Is This an Indication of Further Gains? |
Jazz (JAZZ) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. |
zacks.com |
2025-02-12 12:26:13 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Report 2024 Full Year and Fourth Quarter Financial Results on February 25, 2025 |
DUBLIN , Feb. 11, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2024 full year and fourth quarter financial results on Tuesday, February 25, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. |
prnewswire.com |
2025-02-11 18:15:00 |
Czytaj oryginał (ang.) |
| Why Jazz (JAZZ) is Poised to Beat Earnings Estimates Again |
Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-02-05 15:11:29 |
Czytaj oryginał (ang.) |
| 3 Biotech Stocks With Notable Insider Buying |
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners. |
seekingalpha.com |
2025-01-22 14:29:06 |
Czytaj oryginał (ang.) |
| 3 Oversold Biotech Names |
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels. |
seekingalpha.com |
2025-01-13 14:56:03 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals: Should Sing A Better Tune In 2025 |
Jazz Pharmaceuticals' stock moved nicely higher post-3Q24 report and FDA approval of zanidatamab, despite challenges in its narcolepsy franchise from Avadel's Lumryz. Jazz's neuroscience franchise faces declining Xyrem sales but sees growth in Xywav and Epidiolex. Oncology growth is driven by zanidatamab's approval and other key drugs like Rylaze and Zepzelca, crucial for achieving Vision 2025 sales goals. |
seekingalpha.com |
2024-12-23 14:53:56 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
DUBLIN , Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference. |
prnewswire.com |
2024-12-17 18:15:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces CEO Succession Plan |
Bruce Cozadd, Co-Founder, Chairperson and CEO, Plans to Retire as CEO Upon Appointment of Successor by the End of 2025; Will Continue as Chair of the Board Mr. Cozadd Has Led Growth of Company from Founding to $4 Billion+ in 2024 Expected Total Revenue Board Will Lead Comprehensive Internal and External Search for New CEO; Intended to be Completed in 2025 DUBLIN , Dec. 16, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Bruce Cozadd, Co-Founder, Chairperson and Chief Executive Officer (CEO), has informed the Board of Directors of his intent to retire from his role as CEO upon appointment of the Company's next leader, expected by the end of 2025. |
prnewswire.com |
2024-12-16 18:05:00 |
Czytaj oryginał (ang.) |
| 5 High ROE Stocks to Buy as Volatility Weighs on Markets |
DIS, LDOS, RF, FTNT and JAZZ are some of the stocks with high ROE to profit from as intense volatility spooks markets. |
zacks.com |
2024-12-11 12:26:17 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Showcase New Real-World Evidence Reinforcing Epidiolex® (cannabidiol) Benefits and Broad-Spectrum Efficacy in Treatment-Resistant Epilepsies at the American Epilepsy Society 2024 Annual Meeting |
Data from nine abstracts to be presented, including first data from the EpiCom Trial, a prospective evaluation of behavioral outcomes in patients with tuberous sclerosis complex, which suggests improvements in severity of behavioral symptoms Real-world data from the BECOME (BEhavior, COgnition and More with Epidiolex®) surveys, which show outcomes reported by long-term care facility nurses and tuberous sclerosis complex caregivers For U.S. media and investors only DUBLIN , Dec. 6, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced nine company-sponsored Epidiolex ® (cannabidiol) posters are being presented at the American Epilepsy Society (AES) 2024 Annual Meeting, being held December 6-10 in Los Angeles, California. Data presented at the meeting includes updated analyses of real-world data from the BECOME-TSC (BEhavior, COgnition, and More with Epidiolex) caregiver survey, which characterizes and quantifies seizure and non-seizure outcomes in patients with epilepsy and tuberous sclerosis complex (TSC) treated with Epidiolex. |
prnewswire.com |
2024-12-06 18:05:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®) |
Ziihera, the first and only FDA-approved dual HER2-targeted bispecific antibody for HER2+ (IHC 3+) BTC, is now commercially available in the United States For U.S. media and investors only DUBLIN , Dec. 5, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that zanidatamab-hrii (Ziihera®) 50 mg/mL for injection for intravenous use is recommended by the National Comprehensive Cancer Network® (NCCN ® ) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A treatment option for Biliary Tract Cancers (BTC). Ziihera was granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 20, 2024, for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) BTC, as detected by an FDA-approved test. |
prnewswire.com |
2024-12-05 09:45:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces Ziihera® (zanidatamab-hrii) Investor Webcast on December 11, 2024 |
DUBLIN , Dec. 4, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will host a webcast on Wednesday, December 11, 2024, at 4:30 p.m. ET / 9:30 p.m. |
prnewswire.com |
2024-12-04 18:15:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting |
Data showcased at SABCS and ASH reflect progress and growth of Jazz's research and development in oncology and demonstrate ongoing efforts to redefine what is possible for cancer treatment DUBLIN , Dec. 3, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2024 San Antonio Breast Cancer Symposium (SABCS) from December 10-13 and 13 abstracts at the 66th Annual American Society of Hematology (ASH) Annual Meeting from December 7-10. A trial-in-progress poster presentation at SABCS outlines the trial design of the ongoing Phase 3 EmpowHER-303 trial (NCT06435429), which is evaluating the efficacy and safety of Ziihera® (zanidatamab-hrii) vs trastuzumab with chemotherapy in patients with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan. |
prnewswire.com |
2024-12-03 09:49:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Jazz (JAZZ) Could Surge 44.37%: Read This Before Placing a Bet |
The consensus price target hints at a 44.4% upside potential for Jazz (JAZZ). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-29 12:57:20 |
Czytaj oryginał (ang.) |
| JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer |
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer. |
zacks.com |
2024-11-21 15:11:13 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals receives FDA approval for biliary tract cancer treatment |
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals' drug, zanidatamab-hrii, for the treatment of a type of biliary tract cancer, the company said on Wednesday. |
reuters.com |
2024-11-20 21:59:58 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC) |
Ziihera is the first and only dual HER2-targeted bispecific antibody approved for HER2+ BTC in the U.S. Ziihera received accelerated approval based on results including a 52% objective response rate and median duration of response of 14.9 months as determined by independent central review (ICR) from the HERIZON-BTC-01 clinical trial Company to host investor webcast on Dec. 11, 2024 For U.S. media and investors only DUBLIN , Nov. 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.1 Ziihera was approved under accelerated approval based on a 52% objective response rate (ORR) and a median duration of response (DOR) of 14.9 months as determined by independent central review (ICR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.1 The Phase 3 HERIZON-BTC-302 confirmatory trial is ongoing to evaluate zanidatamab in combination with standard-of-care therapy versus standard-of-care therapy alone in the first-line setting for patients with HER2-positive BTC. |
prnewswire.com |
2024-11-20 21:19:00 |
Czytaj oryginał (ang.) |
| Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference |
DUBLIN , Nov. 19, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in Citi's 2024 Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, December 3, 2024, at 7:15 a.m. |
prnewswire.com |
2024-11-19 18:05:00 |
Czytaj oryginał (ang.) |
| Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock? |
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. |
zacks.com |
2024-11-19 12:45:38 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Jazz (JAZZ) Stock? |
Investors need to pay close attention to Jazz (JAZZ) stock based on the movements in the options market lately. |
zacks.com |
2024-11-14 11:50:31 |
Czytaj oryginał (ang.) |
| Jazz (JAZZ) Upgraded to Buy: Here's Why |
Jazz (JAZZ) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-13 15:06:14 |
Czytaj oryginał (ang.) |
| JAZZ or CTLT: Which Is the Better Value Stock Right Now? |
Investors interested in Medical - Drugs stocks are likely familiar with Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-11-13 14:40:22 |
Czytaj oryginał (ang.) |
| Wall Street Analysts See a 37.65% Upside in Jazz (JAZZ): Can the Stock Really Move This High? |
The mean of analysts' price targets for Jazz (JAZZ) points to a 37.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-11-13 13:00:48 |
Czytaj oryginał (ang.) |
| Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know |
Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock. |
zacks.com |
2024-11-11 12:20:42 |
Czytaj oryginał (ang.) |
| Jazz Tops Q3 Earnings & Sales Estimates, Raises '24 EPS View |
JAZZ reports better-than-expected third-quarter results. After initiating a strategic pipeline prioritization program, the company raises its EPS guidance for 2024 by 30 cents. |
zacks.com |
2024-11-07 14:00:39 |
Czytaj oryginał (ang.) |